News And Notes
May 2008
in “
Trends in Urology Gynaecology & Sexual Health
”
TLDR Loop diuretics may double bone loss in elderly men, finasteride lowers prostate cancer risk but may increase high-grade tumors, abarelix reduces testosterone quickly, and transdermal testosterone offers minimal sexual benefit for women.
The document discussed several medical findings from 2008. A study on 3,269 elderly men indicated that continuous use of loop diuretics could double the rate of bone loss compared to non-users. A Cochrane review found that finasteride reduced prostate cancer risk by about 25%, though it was associated with an increase in high-grade tumors. Germany introduced the GnRH antagonist abarelix for prostate cancer, showing rapid testosterone reduction without hormonal surge. An Australian trial on 261 women found that transdermal testosterone provided little benefit for sexual satisfaction, with only the 90µl dose showing a small, statistically significant increase in satisfactory sexual events. The most common side effect was hypertrichosis.